Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma

Mycophenolate mofetil for localized scleroderma

Commentary Systemic sclerosis is one of the rheumatic diseases that is associated with the worst prognosis. Systemic sclerosis is divided into localized and systemic forms. Localized scleroderma comprises four subtypes, namely morphea, generalized morphea, linear scleroderma and en coup de saber, and is more commonly encountered in children. Although conversion into systemic sclerosis is very u...

Rheumatology 2001;40:1192 Anti-thymocyte globulin in scleroderma

SIR, The detailed study of aggressive immunosuppressive treatment of scleroderma by Stratton et al. [1] is of great interest. Certainly novel approaches are justified in a rheumatic disease which has proved resistant to all forms of treatment. Indeed my colleagues and I instituted a similar trial of anti-thymocyte in combination with other immunosuppressive drugs which was reported in a confere...

A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset.

OBJECTIVE A prospective observational study of mycophenolate mofetil (MMF) treatment in patients with diffuse progressive cutaneous systemic sclerosis (SSc) of recent onset. METHODS Twenty-five previously untreated consecutive patients with recent-onset (< 24 mo) diffuse progressive cutaneous SSc received MMF as the only disease-modifying therapy. Modified Rodnan skin score (mRSS) and affecte...

Relationship between post-transplant lymphoproliferative disorder and Anti-Thymocyte Globulin or Anti-Lymphocyte Globulin

 Abstract Background: Lymphoproliferative disorders are among the most serious and potentially fatal complications of chronic immunosuppression in kidney transplant recipients. The principle risk factors for development of PTLD are the degree of overall immunosuppression and the EBV serostatus of the recipient. In this study, the risk of PTLD in kidney transplant recipients who received Anti- L...

Squamous cell carcinomas in 2 patients with diffuse scleroderma treated with mycophenolate mofetil.